Premium
Therapeutic targets in chronic myeloid leukaemia
Author(s) -
Heaney Nicholas B.,
Holyoake Tessa L.
Publication year - 2007
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.813
Subject(s) - chronic myeloid leukaemia , imatinib mesylate , imatinib , medicine , disease , stem cell , myeloid , cancer research , immunology , myeloid leukemia , biology , genetics
Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a consequence of the formation of the bcr‐abl oncogene. The particular molecular basis of this condition has enabled the development of therapies that selectively target diseased cells. The success of the rationally designed first‐line therapy imatinib mesylate (IM) is tempered by the problems of disease persistence and resistance. Novel strategies have been identified to take forward therapy in CML and these will be discussed in this review. This work is generated from a review of published literature and contains particular insight into the work performed by our group in this field. Copyright © 2007 John Wiley & Sons, Ltd.